AbbVie hepatitis C cocktail succeeds in late-stage study

Last Updated: 2015-06-24

By Reuters Staff

(Reuters) - AbbVie Inc said on Wednesday that its all oral hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with ribavirin against the most common form of the disease (genotype 1b), according to data from a late-stage study.

Viekira Pak, a combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir, was approved in December 2014 for use as both a standalone treatment and in tandem with ribavirin, a broad-spectrum antiviral approved in 1998.

All the patients in the study showed a sustained response to Viekira Pak as a standalone treatment after 12 weeks of treatment, AbbVie said.

The late-stage study on which the U.S. Food and Drug Administration based its decision to approve Viekira Pak in December showed it cured 91-100% of all patients with the infection.